Headlines about Lantheus (NASDAQ:LNTH) have trended somewhat positive on Tuesday, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Lantheus earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 44.9016201385844 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern’s scoring:
- Short Interest in Lantheus Holdings Inc (LNTH) Increases By 75.4% (americanbankingnews.com)
- Lantheus (LNTH) Raised to “Buy” at BidaskClub (americanbankingnews.com)
- Lantheus Holdings, Inc. is trading above its 50 day moving average : LNTH-US : December 28, 2017 (finance.yahoo.com)
- Lantheus Holdings, Inc. (LNTH)- Well recognized Healthcare stock of Market – Nasdaq Fortune (press release) (nasdaqfortune.com)
- What is ATR in technical analysis? Lantheus Holdings, Inc. (LNTH) – Wall Street Morning (wallstreetmorning.com)
Shares of Lantheus (NASDAQ LNTH) opened at $20.45 on Tuesday. Lantheus has a 12 month low of $7.95 and a 12 month high of $24.10. The firm has a market cap of $767.00, a PE ratio of 25.25, a PEG ratio of 1.62 and a beta of 0.94. The company has a current ratio of 2.96, a quick ratio of 2.46 and a debt-to-equity ratio of -3.41.
LNTH has been the subject of several recent research reports. Jefferies Group increased their target price on shares of Lantheus from $22.00 to $27.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. BidaskClub downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, December 5th. ValuEngine downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Zacks Investment Research downgraded shares of Lantheus from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 9th. Finally, Credit Suisse Group increased their target price on shares of Lantheus from $19.00 to $23.00 and gave the stock a “neutral” rating in a research note on Friday, November 3rd. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $24.50.
In related news, insider Michael P. Duffy sold 11,917 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $21.63, for a total value of $257,764.71. Following the completion of the sale, the insider now owns 152,301 shares in the company, valued at $3,294,270.63. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO John W. Crowley sold 6,755 shares of the firm’s stock in a transaction dated Friday, October 13th. The shares were sold at an average price of $18.41, for a total transaction of $124,359.55. The disclosure for this sale can be found here. In the last 90 days, insiders sold 29,986 shares of company stock valued at $625,488. 2.30% of the stock is owned by insiders.
Lantheus Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.